John F. Gerecitano

Correction: Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni RA Razak et autres

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

Zachary Drew Epstein-Peterson, Esther N Drill, Umut Aypar, Connie Lee Batlevi et autres

us (code pays fourni par la source)

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

Zachary Drew Epstein-Peterson, Esther N Drill, Umut Aypar, Connie Lee Batlevi et autres

Chemoimmunotherapy followed by consolidative high-dose therapy with autologous stem cell rescue was a standard upfront treatment for fit patients with mantle cell lymphoma (MCL) in first remission; however, treatment paradigms are evolving in the era of novel therapies. Lenalidomide is an immunomodulatory …

us (code pays fourni par la source)

P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Matko Kalac, Mark Hertzberg, Chan Yoon Cheah, Vincent Ribrag et autres

Background: MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a key component of the CARD11-BCL10-MALT1 (CBM) complex, which activates the classical NF-κB pathway. JNJ-67856633, a highly selective protease inhibitor of CBM-mediated NF-κB signaling, has demonstrated potent anti-lymphoma activity preclinically in vitro …

us, au, fr, es, cn, jp, be (code pays fourni par la source)

PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Mark Hertzberg, Matko Kalac, Chan Yoon Cheah, Vincent Ribrag et autres

Introduction: MALT1 is a key component of the CARD11-BCL10-MALT1 (CBM) complex, which activates the classical NF-κB pathway. JNJ-67856633 (JNJ-6633), a highly selective protease inhibitor of CBM-mediated NF-κB signaling, demonstrated potent anti-lymphoma activity in preclinical models. Here, we present results from a phase …

au, us, fr, es, cn, jp, be (code pays fourni par la source)

Supplementary Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Caitlin M. Stewart, Laure Michaud, Karissa A. Whiting, Reiko Nakajima et autres

Supplemental text and tables

Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Caitlin M. Stewart, Laure Michaud, Karissa A. Whiting, Reiko Nakajima et autres

AbstractPurpose: Activation of Bruton tyrosine kinase (BTK) and phosphatidylinositol-3-kinase (PI3K) represent parallel, synergistic pathways in lymphoma pathogenesis. As predominant PI3Kδ inhibition is a possible mechanism of tumor escape, we proposed a clinical trial of dual BTK and pan-PI3K inhibition. Patients and Methods: …

us (code pays fourni par la source)

Supplemental Figure 4 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Caitlin M. Stewart, Laure Michaud, Karissa A. Whiting, Reiko Nakajima et autres

Supplemental Figure S4. Progression-free survival Kaplan-Meier curves based on PET and ctDNA parameters. A. PFS based on baseline SUV categorized into lower and higher than median. B. PFS based on baseline tumor glycolysis level lower or higher than median. C. PFS based …

Supplemental Figure 3 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Caitlin M. Stewart, Laure Michaud, Karissa A. Whiting, Reiko Nakajima et autres

Supplemental Figure S3. A. Waterfall plot based on RECIL criteria. RECIL introduces the minimal response category which is a 10-30% reduction in the sum of longest diameters of target lesions. B. Event-free survival Kaplan-Meier curve.

Supplemental Figure 2 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Caitlin M. Stewart, Laure Michaud, Karissa A. Whiting, Reiko Nakajima et autres

Supplemental Figure S2. A. Comparison of treatment-related and -unrelated adverse events occurring in >10% of evaluable patients.

Supplementary Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Caitlin M. Stewart, Laure Michaud, Karissa A. Whiting, Reiko Nakajima et autres

Genomic alteration calls and clinical data

Supplementary Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Caitlin M. Stewart, Laure Michaud, Karissa A. Whiting, Reiko Nakajima et autres

Genomic alteration calls and clinical data